HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Read responses to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rajagopal, S Search for Related Content PubMed PubMed Citation Articles by Rajagopal, S

Clozapine, agranulocytosis, and benign ethnic neutropenia

Correspondence to:
Correspondence to:
Dr S Rajagopal
South London and Maudsley NHS Trust, Adamson Centre for Mental Health, St Thomas’s Hospital, London SE1 7EH, UK; Sundararajan.Rajagopal@slam.nhs.uk

Keywords: clozapine; agranulocytosis; neutropenia; ethnic; benign

The first 150 words of the full text of this article appear below.

Clozapine is an atypical antipsychotic that is effective in treatment resistant schizophrenia.¹ The National Institute for Health and Clinical Excellence (NICE) guidelines for schizophrenia specify that "in individuals with evidence of treatment resistant schizophrenia, clozapine should be introduced at the earliest opportunity".²

A severe adverse effect of clozapine that limits its more widespread use is agranulocytosis. Patients who are taking clozapine need to have their full blood counts (FBC) monitored regularly, and if the total white cell and/or neutrophil counts indicate agranulocytosis, clozapine prescription must be terminated. Among certain ethnic groups, a significant proportion of people have a low baseline neutrophil count. This is called benign ethnic neutropenia (BEN). This editorial looks at the important issues associated with agranulocytosis and BEN in patients receiving clozapine.

CLOZAPINE AND AGRANULOCYTOSIS
Agranulocytosis occurs in about 1% of patients taking clozapine.^3,4 Neutropenia is seen in about 3%.⁴ The risk of both agranulocytosis and neutropenia . . . [Full text of this article]

This article has been cited by other articles:

				S. Ghaznavi, M. Nakic, P. Rao, J. Hu, J. A. Brewer, J. Hannestad, and Z. Bhagwagar Rechallenging With Clozapine Following Neutropenia: Treatment Options for Refractory Schizophrenia Am J Psychiatry, July 1, 2008; 165(7): 813 - 818. [Full Text] [PDF]

				D. L. Kelly, J. Kreyenbuhl, L. Dixon, R. C. Love, D. Medoff, and R. R. Conley Clozapine Underutilization and Discontinuation in African Americans Due to Leucopenia Schizophr Bull, September 1, 2007; 33(5): 1221 - 1224. [Abstract] [Full Text] [PDF]

eLetters: